Gilead Sciences: Harvoni Launch ‘Off to a Strong Start’

Barclays’ Geoff Meacham and Marck Purcell believe “survey data from ImpactRx highlights bullish trends for Gilead Sciences (GILD).” They explain: Sipa USA/Associated Press Survey data from ImpactRx highlights bullish trends for Gilead. The Harvoni launch is off to a strong start and clarity on discounting has shifted the Street focus to volume/market share trends between [...]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.